|
Name |
Veritas In Silico Inc. |
|
|
Headquarters |
1-11-1 Nishigotanda, Shinagawa-ku, Tokyo 141-0031 Japan |
|
|
Research Institute |
Kawasaki Research Institute |
Kanagawa, Japan |
|
Niigata Research Institute |
Niigata, Japan |
|
|
Established |
November 17, 2016 |
|
|
Employees |
23 (as of June 1, 2026) |
|
|
Business Description |
Creating mRNA-targeted small molecule drugs with pharmaceutical companies as partner, utilizing our proprietary drug discovery platform, aibVIS, as well as developing nucleic acid medicine as its pipelines. |
|
Inspired by the Latin saying in vino veritas or “in wine there is truth,” Veritas In Silico means that the truth will be revealed through computer-powered biological research.
The company name conveys our strengths, approaching the truth through deduction by using in silico technologies and verifying such truths using experimental biology approaches that enable the discovery of mRNA-targeted drugs.
|
2026 |
2026.5 |
Entered into a joint research agreement to initiate the discovery of next generation mRNA binding chemical matter |
|
2026.4 |
Relocated and expanded the Shin-Kawasaki Research Institute to establish Kawasaki Research Institute |
|
|
2026.1 |
Upgraded the proprietary drug discovery platform ibVIS® to aibVIS |
|
|
2025 |
2025.12 |
Granted a Japanese patent for the drug delivery system, Perfusio |
|
2025.7 |
Granted a U.S. patent for the business model of RNA-targeting small molecule drug discovery |
|
|
2025.6 |
Entered into a collaborative research agreement with Mitsubishi Gas Chemical Company, Inc. to create nucleic acid therapeutics and establish manufacturing methodologies |
|
|
2025.6 |
Launched a therapeutic project utilizing nucleic acid medicine aimed at establishing a proprietary pipeline |
|
|
2025.4 |
Adopted an executive officer system to strengthen corporate governance |
|
|
2025.1 |
Successfully secured a European patent for the business model of RNA-targeting small molecule drug discovery |
|
|
2024 |
2024.12 |
Enter into a collaboration development & commercialisation agreement for mRNA-targeted small molecule drugs |
|
2024.2 |
Listed on the Tokyo Stock Exchange Growth Market |
|
|
2023 |
2023.6 |
Entered into a joint drug discovery research agreement with Takeda Pharmaceutical Company Limited for mRNA-targeted small molecule drugs |
|
2023.5 |
Initiated a strategic business collaboration with Oncodesign Services (France) for the development of mRNA-targeted small molecule drugs |
|
|
2022 |
2022.12 |
Entered into a joint drug discovery research agreement with RaQualia Pharma Inc. for mRNA-targeted small molecule drugs |
|
2021 |
2021.11 |
Entered into a joint drug discovery research agreement with Shionogi & Co., Ltd. for mRNA-targeted small molecule drugs |
|
2021.7 |
Entered into a joint drug discovery research agreement with Toray Industries, Inc. for mRNA-targeted small molecule drugs |
|
|
2020 |
2020.10 |
Granted a Japanese patent for the business model of RNA-targeting small molecule drug discovery |
|
2019 |
2019.3 |
Formulated a strategic directive to focus resources exclusively on the mRNA-targeting small molecule drug discovery platform business |
|
2018 |
2018.4 |
Established a dedicated research institute (subsequently the Shin-Kawasaki Laboratory) to advance mRNA-targeting small molecule drug discovery |
|
2018.4 |
Strategically pivoted the core business from nucleic acid drugs to an mRNA-targeted small molecule drug discovery platform business |
|
|
2018.3 |
Initiated collaborative research with pharmaceutical companies on mRNA-targeted small molecule drug discovery |
|
|
2017 |
2017.10 |
Relocated the corporate headquarters to Shinagawa-ku, Tokyo |
|
2017.7 |
Established a research site (currently: Niigata Research Institute) in Niigata University of Pharmacy and Medical and Life Sciences, a collaborative research partner |
|
|
2017.5 |
Commenced drug discovery research on mRNA-targeting nucleic acid therapeutics as the core business |
|
|
2016 |
2016.11 |
Established Veritas In Silico Inc. in Shibuya-ku, Tokyo |